Hydroxysafflor yellow A protects against colitis in mice by suppressing pyroptosis via inhibiting HK1/NLRP3/GSDMD and modulating gut microbiota

Chen, Jiaxi; Pan, Mengyue; Wang, Jingjie; Zhang, Mengling; Feng, Mingmei; Chai, Xiaoming; Zhang, Qi; Sun, Yang

doi:10.1016/j.taap.2023.116494

Cited by 11 publications

(5 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ability of HSYA to reduce the expression of inflammatory factors such as IL-1β, IL-6, TNF-α, and IL-18 by modulating the GSDMD/NLRP3 signaling pathway was confirmed by in vivo and in vitro studies. In addition, 16SrRNA sequencing showed that HSYA could also improve the gut microbial population in the model group (Chen et al, 2023). Honokiol is the main natural active product extracted from Magnolia officinalis Rehd.…”

Section: Compounds Targeted To Regulate the Pyroptosis Pathwaymentioning

confidence: 99%

Natural compounds target programmed cell death (PCD) signaling mechanism to treat ulcerative colitis: a review

Chen,

Dong,

Zhang

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Ulcerative colitis (UC) is a nonspecific inflammatory bowel disease characterized by abdominal pain, bloody diarrhea, weight loss, and colon shortening. However, UC is difficult to cure due to its high drug resistance rate and easy recurrence. Moreover, long-term inflammation and increased disease severity can lead to the development of colon cancer in some patients. Programmed cell death (PCD) is a gene-regulated cell death process that includes apoptosis, autophagy, necroptosis, ferroptosis, and pyroptosis. PCD plays a crucial role in maintaining body homeostasis and the development of organs and tissues. Abnormal PCD signaling is observed in the pathological process of UC, such as activating the apoptosis signaling pathway to promote the progression of UC. Targeting PCD may be a therapeutic strategy, and natural compounds have shown great potential in modulating key targets of PCD to treat UC. For instance, baicalin can regulate cell apoptosis to alleviate inflammatory infiltration and pathological damage. This review focuses on the specific expression of PCD and its interaction with multiple signaling pathways, such as NF-κB, Nrf2, MAPK, JAK/STAT, PI3K/AKT, NLRP3, GPX4, Bcl-2, etc., to elucidate the role of natural compounds in targeting PCD for the treatment of UC. This review used (ulcerative colitis) (programmed cell death) and (natural products) as keywords to search the related studies in PubMed and the Web of Science, and CNKI database of the past 10 years. This work retrieved 72 studies (65 from the past 5 years and 7 from the past 10 years), which aims to provide new treatment strategies for UC patients and serves as a foundation for the development of new drugs.

show abstract

Section: Compounds Targeted To Regulate the Pyroptosis Pathwaymentioning

confidence: 99%

Natural compounds target programmed cell death (PCD) signaling mechanism to treat ulcerative colitis: a review

Chen,

Dong,

Zhang

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“… 239 Hydroxysafflor yellow A, a chalcone glycoside isolated from safflower has been found to ameliorate DSS-induced colitis mice via suppressing pyroptosis by blocking hexokinase 1/NLRP3/gasdermin D pathway and regulating intestinal microbiota. 240 Ginsenoside Rg3 could interfere with NLRP3 inflammasome activation and inhibit pyroptosis, leading to the restoration of barrier function. 241 Kumatakenin, the main components of cloves and Alpinia purpurata upregulate the expression of enolase by hydrogen bonding with the amino acid residues Thr208, Val206, and Pro203, leading to the degradation of IRP1 mRNA, which inhibits epithelial ferroptosis to relieve IBD.…”

Section: Ibd Treatments: Based On Experimentsmentioning

confidence: 99%

Research advancements and perspectives of inflammatory bowel disease: A comprehensive review

Bai,

Wang,

et al. 2024

Science Progress

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a chronic inflammatory disease with increasing incidence, such as Crohn's disease and ulcerative colitis. The accurate etiology and pathogenesis of IBD remain unclear, and it is generally believed that it is related to genetic susceptibility, gut microbiota, environmental factors, immunological abnormalities, and potentially other factors. Currently, the mainstream therapeutic drugs are amino salicylic acid agents, corticosteroids, immunomodulators, and biological agents, but the remission rates do not surpass 30–60% of patients in a real-life setting. As a consequence, there are many studies focusing on emerging drugs and bioactive ingredients that have higher efficacy and long-term safety for achieving complete deep healing. This article begins with a review of the latest, systematic, and credible summaries of the pathogenesis of IBD. In addition, we provide a summary of the current treatments and drugs for IBD. Finally, we focus on the therapeutic effects of emerging drugs such as microRNAs and lncRNAs, nanoparticles-mediated drugs and natural products on IBD and their mechanisms of action.

show abstract

“…In turn, reintegrating the potential shown in this manuscript of medicinal herbs and their phytocompounds in treating inflammatory bowel-related conditions, it is crucial to conduct further experiments and clinical trials focusing on IBD therapy through NLRP3-modulating natural agents. Shortly, numerous clinical studies will be necessary to validate the therapeutic benefits of phytochemicals that target NLRP3 in treating IBD due to the elevated prices of synthetic medicines and their deleterious adverse events [ 104 , 105 , 106 ]. In the current conditions of global environmental change and also significant declines in fauna and flora biodiversity, preserving medicinal plants for treating human illnesses and maintaining the associated local ecological knowledge plays a fundamental role in not only achieving the Sustainable Development Goal of promoting good health but also well-being for all [ 2 , 107 , 108 , 109 ].…”

Section: Future Research Directionsmentioning

confidence: 99%

Medicinal Plants, Phytochemicals and Regulation of the NLRP3 Inflammasome in Inflammatory Bowel Diseases: A Comprehensive Review

et al. 2023

View full text Add to dashboard Cite

Ongoing research explores the underlying causes of ulcerative colitis and Crohn’s disease. Many experts suggest that dysbiosis in the gut microbiota and genetic, immunological, and environmental factors play significant roles. The term “microbiota” pertains to the collective community of microorganisms, including bacteria, viruses, and fungi, that reside within the gastrointestinal tract, with a particular emphasis on the colon. When there is an imbalance or disruption in the composition of the gut microbiota, it is referred to as dysbiosis. Dysbiosis can trigger inflammation in the intestinal cells and disrupt the innate immune system, leading to oxidative stress, redox signaling, electrophilic stress, and inflammation. The Nod-like Receptor (NLR) Family Pyrin Domain Containing 3 (NLRP3) inflammasome, a key regulator found in immunological and epithelial cells, is crucial in inducing inflammatory diseases, promoting immune responses to the gut microbiota, and regulating the integrity of the intestinal epithelium. Its downstream effectors include caspase-1 and interleukin (IL)-1β. The present study investigated the therapeutic potential of 13 medicinal plants, such as Litsea cubeba, Artemisia anomala, Piper nigrum, Morus macroura, and Agrimonia pilosa, and 29 phytocompounds such as artemisitene, morroniside, protopine, ferulic acid, quercetin, picroside II, and hydroxytyrosol on in vitro and in vivo models of inflammatory bowel diseases (IBD), with a focus on their effects on the NLRP3 inflammasome. The observed effects of these treatments included reductions in IL-1β, tumor necrosis factor-alpha, IL-6, interferon-gamma, and caspase levels, and increased expression of antioxidant enzymes, IL-4, and IL-10, as well as regulation of gut microbiota. These effects could potentially provide substantial advantages in treating IBD with few or no adverse effects as caused by synthetic anti-inflammatory and immunomodulated drugs. However, additional research is necessary to validate these findings clinically and to develop effective treatments that can benefit individuals who suffer from these diseases.

show abstract

Hydroxysafflor yellow A protects against colitis in mice by suppressing pyroptosis via inhibiting HK1/NLRP3/GSDMD and modulating gut microbiota

Cited by 11 publications

References 73 publications

Natural compounds target programmed cell death (PCD) signaling mechanism to treat ulcerative colitis: a review

Natural compounds target programmed cell death (PCD) signaling mechanism to treat ulcerative colitis: a review

Research advancements and perspectives of inflammatory bowel disease: A comprehensive review

Medicinal Plants, Phytochemicals and Regulation of the NLRP3 Inflammasome in Inflammatory Bowel Diseases: A Comprehensive Review

Contact Info

Product

Resources

About